Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Holding BEAM?
Track your performance easily
BEAM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.95 - $49.50
Previous Close$26.68
Volume389.98K
Average Volume (3M)1.24M
Market Cap
$2.21B
Enterprise Value$1.37B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$165.24M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Nov 04, 2024EPS Estimate
-$1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding82,415,619
10 Day Avg. Volume698,584
30 Day Avg. Volume1,240,837
Standard Deviation0.26
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.65
Price to Sales (P/S)6.27
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.88
Enterprise Value/Gross Profit3.62
Enterprise Value/Ebitda-10.39
Forecast
1Y Price Target
$47.50Price Target Upside78.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Beam Therapeutics News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient has been dosed in the open-label dose escalation Ph1/2 study evaluating BEAM-302 in AATD patients.
Commercial OpportunityBeam's single-course administration and robust safety/efficacy profile represent a significant commercial opportunity given the high unmet need in AATD.
Financial StabilityThe company ended the first quarter with $1.1 billion in cash and equivalents, providing financial stability into 2027.
Bears Say
Clinical TrialsVERV has paused enrollment in the Phase 1b Heart-1 trial due to safety concerns.
Financial PerformanceThe price target for VERV has been reduced from $28 to $27 following the recent developments.
Investor SentimentSafety concerns from the VERVE-101 trial have led to heightened investor focus on the safety of similar programs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $16.95 and its highest was $49.50 in the past 12 months.
What is Beam Therapeutics’s market cap?
Currently, no data Available
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Nov 04, 2024 which is in 65 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Aug 06, 2024. The company reported -$1.11 earnings per share for the quarter, beating the consensus estimate of -$1.127 by $0.017.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -$1.19.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 82,415,620 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.11 in its last earnings report, beating expectations of -$1.127. Following the earnings report the stock price went down -0.351%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Among the largest hedge funds holding Beam Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Beam Therapeutics’s shares valued at 185M.
---
Beam Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.50 (78.04% Upside)
$47.50 (78.04% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 80%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.48%
12-Months-Change
Fundamentals
Return on Equity
-17.17%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Stock 12 Month Forecast
Average Price Target
$47.50
▲(78.04% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
-0.07%
assigned a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of -0.07% per trade.
---